Shukra Pharmaceuticals Limited (BOM:524632)
India
· Delayed Price · Currency is INR 18.12
-0.74 (-3.92%)
At close: Apr 24, 2025
Shukra Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Operating Revenue | 302.01 | 745.73 | 588.34 | 204.86 | 111.96 | 118.46 | Upgrade
|
| Other Revenue | 31.96 | 18.93 | 6.59 | -0 | - | - | Upgrade
|
| Revenue | 333.97 | 764.66 | 594.93 | 204.86 | 111.96 | 118.46 | Upgrade
|
| Revenue Growth (YoY) | -70.11% | 28.53% | 190.41% | 82.97% | -5.49% | 109.31% | Upgrade
|
| Cost of Revenue | 80.21 | 445.34 | 454.25 | 105.17 | 27.69 | 30.01 | Upgrade
|
| Gross Profit | 253.76 | 319.31 | 140.68 | 99.69 | 84.27 | 88.45 | Upgrade
|
| Selling, General & Admin | 84.69 | 81.76 | 53.83 | 55.4 | 44.76 | 48.66 | Upgrade
|
| Other Operating Expenses | 35.04 | 20.96 | 21.88 | 14.94 | 21.97 | 24.39 | Upgrade
|
| Operating Expenses | 145.51 | 123.22 | 94.09 | 86.96 | 81.47 | 87.83 | Upgrade
|
| Operating Income | 108.25 | 196.09 | 46.59 | 12.73 | 2.8 | 0.62 | Upgrade
|
| Interest Expense | -3.85 | -2.76 | -2.56 | -2.81 | -0.13 | - | Upgrade
|
| Interest & Investment Income | 5.59 | 5.59 | 0.64 | 0.31 | 0.47 | 0.08 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | - | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.09 | -0.09 | -0.25 | -0.05 | -0.2 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | 109.9 | 198.83 | 44.42 | 10.18 | 2.93 | 0.7 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 1.03 | Upgrade
|
| Other Unusual Items | - | - | - | - | -1.95 | -0.02 | Upgrade
|
| Pretax Income | 109.9 | 198.83 | 44.42 | 10.18 | 0.98 | 1.71 | Upgrade
|
| Income Tax Expense | 28.15 | 13.46 | 0.35 | 2.67 | -0.9 | 1.35 | Upgrade
|
| Net Income | 81.75 | 185.37 | 44.07 | 7.51 | 1.88 | 0.36 | Upgrade
|
| Net Income to Common | 81.75 | 185.37 | 44.07 | 7.51 | 1.88 | 0.36 | Upgrade
|
| Net Income Growth | -55.88% | 320.68% | 486.98% | 299.10% | 428.31% | -92.29% | Upgrade
|
| Shares Outstanding (Basic) | 437 | 438 | 67 | 63 | 63 | 63 | Upgrade
|
| Shares Outstanding (Diluted) | 437 | 438 | 67 | 63 | 63 | 63 | Upgrade
|
| Shares Change (YoY) | 25.21% | 551.03% | 7.38% | - | 0.02% | - | Upgrade
|
| EPS (Basic) | 0.19 | 0.42 | 0.66 | 0.12 | 0.03 | 0.01 | Upgrade
|
| EPS (Diluted) | 0.19 | 0.42 | 0.66 | 0.12 | 0.03 | 0.01 | Upgrade
|
| EPS Growth | -64.76% | -35.38% | 446.67% | 299.10% | 428.20% | -92.29% | Upgrade
|
| Free Cash Flow | - | -69.57 | -13.22 | 64.39 | -12.54 | -19.6 | Upgrade
|
| Free Cash Flow Per Share | - | -0.16 | -0.20 | 1.03 | -0.20 | -0.31 | Upgrade
|
| Dividend Per Share | - | 0.100 | 0.013 | 0.013 | - | - | Upgrade
|
| Dividend Growth | - | 700.00% | - | - | - | - | Upgrade
|
| Gross Margin | 75.98% | 41.76% | 23.65% | 48.66% | 75.27% | 74.66% | Upgrade
|
| Operating Margin | 32.41% | 25.64% | 7.83% | 6.21% | 2.50% | 0.53% | Upgrade
|
| Profit Margin | 24.48% | 24.24% | 7.41% | 3.66% | 1.68% | 0.30% | Upgrade
|
| Free Cash Flow Margin | - | -9.10% | -2.22% | 31.43% | -11.20% | -16.54% | Upgrade
|
| EBITDA | 130.35 | 216.59 | 64.96 | 29.35 | 17.53 | 15.4 | Upgrade
|
| EBITDA Margin | 39.03% | 28.33% | 10.92% | 14.33% | 15.66% | 13.00% | Upgrade
|
| D&A For EBITDA | 22.1 | 20.5 | 18.38 | 16.62 | 14.74 | 14.78 | Upgrade
|
| EBIT | 108.25 | 196.09 | 46.59 | 12.73 | 2.8 | 0.62 | Upgrade
|
| EBIT Margin | 32.41% | 25.64% | 7.83% | 6.21% | 2.50% | 0.53% | Upgrade
|
| Effective Tax Rate | 25.62% | 6.77% | 0.79% | 26.26% | - | 79.16% | Upgrade
|
| Revenue as Reported | 343.2 | 773.88 | 600.3 | 205.67 | 115.52 | 118.56 | Upgrade
|
| Advertising Expenses | - | 21.21 | 0.1 | 0.09 | 0.41 | 0.02 | Upgrade
|
Updated Feb 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.